TSLP and idiopathic pulmonary fibrosis: Elevated systemic and lung compartment TSLP levels in patients with IPF compared to controls and their significant decrease in the lung compartment during antifibrotic therapy in stable patients with IPF, but not in progressors, support its significant contribution to profibrotic type 2 immune responses in IPF.